References
- Schuh A, Dandridge J, Haydon P, Littlewood TJ. Encephalopathy complicating high-dose melphalan. Bone Marrow Transplant. 1999;24(10):1141–3.
- Focosi D, Pelosini M, Palla P, Galimberti S, Caracciolo F, Benedetti E, et al. Hypercytokinemia-induced metabolic encephalopathy in a multiple myeloma patient on hemodialysis undergoing autologous stem cell transplantation: clinical response after plasma exchange. Transpl Immunol. 2009;21(4):240–3.
- Alayon-Laguer D, Alsina M, Ochoa-Bayona JL, Ayala E. Melphalan culprit or confounder in acute encephalopathy during autologous hematopoietic stem cell transplantation? Case Rep Transplant. 2012;2012:942795.
- Najera JE, Sudhakar T, Bashir Q, Shah N, Champlin RE, Qazilbash MH, et al. Neurotoxicity after high-dose melphalan. J Clin Oncol. 2012;30(Suppl):abstr 6546.
- Badros A, Barlogie B, Siegel E, Roberts J, Langmaid C, Zangari M, et al. Results of autologous stem cell transplant in multiple myeloma patients with renal failure. Br J Haematol. 2001;114:822–9.
- Tricot G, Alberts DS, Johnson C, Roe DJ, Dorr RT, Bracy D, et al. Safety of autotransplants with high-dose melphalan in renal failure: a pharmacokinetic and toxicity study. Clin Cancer Res. 1996;2:947–52.
- Lyman M, Lloyd DG, Ji X, Vizcaychipi MP, Ma D. Neuroinflammation: the role and consequences. Neurosci Res. 2014;79:1–12.
- Yonekawa C, Nakae H, Tajimi K, Asanuma Y. Combining continuous endotoxin apheresis and continuous hemodiafiltration in the treatment of patients with septic multiple organ dysfunction syndrome. Ther Apher Dial. 2006;10(1):19–24.
- Madzar D, Maihofner C, Zimmermann R, Schwab S, Kornhuber J, Lewczuk P. Cerebrospinal fluid under non-steady state condition caused by plasmapheresis. J Neural Transm. 2011;118(2):219–22.
- Shu KH, Lu YS, Cheng CH, Lian JD. Soluble interleukin 2 receptor in dialyzed patients. Artif Organs. 1998;22(2):142–4.